EcoDrugPlus

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSOKIG00005030079
Gene Symbol: LOC109881685
3 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSOKIG00005045370
Gene Symbol: LOC109875896
3 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSOKIG00005033908
Gene Symbol: HTR3A
1 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSOKIG00005048545
Gene Symbol: HTR3A
1 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSOKIG00005033870
Gene Symbol: HTR3B
1 Cross references
168 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSOKIG00005048539
Gene Symbol: HTR3B
1 Cross references
170 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSOKIG00005013060
Gene Symbol: HTR4
3 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSOKIG00005039049
Gene Symbol: HTR4
3 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSOKIG00005021908
Gene Symbol: HTR5A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSOKIG00005032404
Gene Symbol: HTR5A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSOKIG00005022213
Gene Symbol: HTR7
3 Cross references
147 Possible Orthologues:

5-Hydroxytryptamine Receptor 7-Like

Ensembl ID : ENSOKIG00005007323
Gene Symbol: LOC109865121
2 Cross references
147 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).